• Home
  | 
• Full Prescribing Information
  | 
• About CRESTOR
  | 
• Clinical Experience
  | 
• Resources
  | 
• Patient Support
  | 
• References

Use in Specific Populations: Comparative Data

In this section, you can review results from comparative clinical trials in which CRESTOR^® (rosuvastatin calcium) was used as an adjunct to diet in African-American and Hispanic-American patients.

TRIAL: ARIES

Back to top

LDL-C reductions vs atorvastatin in African-American adults with hypercholesterolemia¹

*P<.01 CRESTOR 10 mg vs atorvastatin 10 mg.
P=NS CRESTOR 10 mg vs atorvastatin 20 mg.
^†P<.0001 CRESTOR 20 mg vs atorvastatin 20 mg.

Mean baseline LDL-C: 189 mg/dL to 192 mg/dL.

CRESTOR 10 mg n=186
atorvastatin 10 mg n=179
CRESTOR 20 mg n=189
atorvastatin 20 mg n=178

Adapted from the ARIES Trial.¹ ARIES was a 6-week, randomized, open-label, comparative, multicenter study. Following a 6-week dietary lead-in period, 774 self-described African-American adults with hypercholesterolemia were randomized to receive either CRESTOR 10 mg or 20 mg or atorvastatin 10 mg or 20 mg for 6 weeks. The primary end point was the percentage change from baseline in LDL-C at week 6.

TRIAL: ARIES

Back to top

HDL-C increases vs atorvastatin in African-American adults with hypercholesterolemia¹

*P<.01 CRESTOR 10 mg vs atorvastatin 20 mg.
P=NS CRESTOR 10 mg vs atorvastatin 10 mg.
P=NS CRESTOR 20 mg vs atorvastatin 20 mg

Mean baseline HDL-C: 50 mg/dL to 53 mg/dL.

CRESTOR 10 mg n=186
atorvastatin 10 mg n=179
CRESTOR 20 mg n=189
atorvastatin 20 mg n=178

Adapted from the ARIES trial.¹ ARIES was a 6-week, randomized, open-label, comparative, multicenter study. Following a 6-week dietary lead-in period, 774 self-described African-American adults with hypercholesterolemia were randomized to receive either CRESTOR 10 mg or 20 mg or atorvastatin 10 mg or 20 mg for 6 weeks. The primary endpoint was the percentage change from baseline in LDL-C at week 6. Percentage change from baseline in HDL-C was a secondary endpoint.

TRIAL: STARSHIP

Back to top

LDL-C reductions vs atorvastatin in Hispanic-American adults with CHD, CHD risk equivalent, or a 10-year CHD risk score ≥10% and hypercholesterolemia²

*P<.0001 vs atorvastatin 10 mg, P=NS CRESTOR 10 mg vs atorvastatin 20 mg.
^†P<.0001 vs atorvastatin 20 mg.

Mean baseline LDL-C: 159 mg/dL to 165 mg/dL.

CRESTOR 10 mg n=174
atorvastatin 10 mg n=161
CRESTOR 20 mg n=167
atorvastatin 20 mg n=161

Adapted from the STARSHIP Trial.² STARSHIP was a 6-week, randomized, open-label, comparative, multicenter study. Following a 6-week dietary lead-in period, 696 Hispanic-American adults with CHD, CHD risk equivalent, or a 10-year CHD risk score ≥10% and hypercholesterolemia were randomized to 1 of 4 arms: CRESTOR 10 mg or 20 mg or atorvastatin 10 mg or 20 mg once daily for 6 weeks. The primary end point was the percentage change in LDL-C from baseline at 6 weeks.

TRIAL: STARSHIP

Back to top

NCEP ATP III LDL-C Goal Attainment <100 mg/dL in high-risk* Hispanic-American adults^2,3

*CHD or CHD risk equivalent (other atherosclerotic disease, diabetes, 10-year CHD risk score >20%)

^†P=.001 vs atorvastatin 10 mg; P=NS CRESTOR 10 mg vs atorvastatin 20 mg.
^‡P<.0001 vs atorvastatin 20 mg.

Mean baseline LDL-C: 156 mg/dL to 166 mg/dL.

CRESTOR 10 mg n=116
atorvastatin 10 mg n=106
CRESTOR 20 mg n=106
atorvastatin 20 mg n=106

This retrospective analysis of goal attainment was adapted from the STARSHIP trial.

Adapted from the STARSHIP trial.² STARSHIP was a 6-week, randomized, open-label, comparative, multicenter study. Following a 6-week dietary lead-in period, 696 Hispanic-American adults with CHD, CHD risk equivalent, or a 10-year CHD risk score ≥10% and hypercholesterolemia were randomized to 1 of 4 arms: CRESTOR 10 mg or 20 mg or atorvastatin 10 mg or 20 mg once daily for 6 weeks. The primary end point was the change in LDL-C at 6 weeks. The percentage of patients achieving NCEP ATP III LDL-C goal of <100 mg/dL was a secondary end point.

Important Safety Information for CRESTOR Tablets

• CRESTOR is contraindicated in patients with a known hypersensitivity to any component of this product, in patients with active liver disease, which may include unexplained persistent elevations of hepatic transaminase levels, in women who are pregnant or may become pregnant, and in nursing mothers
• Cases of myopathy and rhabdomyolysis with acute renal failure secondary to myoglobinuria have been reported with HMG-CoA reductase inhibitors, including CRESTOR. These risks can occur at any dose level but are increased at the highest dose (40 mg)
• CRESTOR should be prescribed with caution in patients with predisposing factors for myopathy (eg, age ≥65 years, inadequately treated hypothyroidism, renal impairment). The risk of myopathy during treatment with CRESTOR may be increased with concurrent administration of some other lipid-lowering therapies (fibrates or niacin), gemfibrozil, cyclosporine, lopinavir/ritonavir, or atazanavir/ritonavir
• Therapy with CRESTOR should be discontinued if markedly elevated CK levels occur or myopathy is diagnosed or suspected. All patients should be advised to promptly report unexplained muscle pain, tenderness, or weakness, particularly if accompanied by malaise or fever
• It is recommended that liver enzyme tests be performed before and at 12 weeks following both the initiation of therapy and any elevation of dose, and periodically (eg, semiannually) thereafter. Should an increase in ALT or AST of >3 times ULN persist, reduction of dose or withdrawal of CRESTOR is recommended
• CRESTOR should be used with caution in patients who consume substantial quantities of alcohol and/or have a history of chronic liver disease
• CRESTOR significantly increased INR in patients receiving coumarin anticoagulants. In patients taking coumarin anticoagulants and CRESTOR concomitantly, INR should be determined before starting CRESTOR and frequently enough during early therapy to ensure that no significant alteration of INR occurs
• Dipstick-positive proteinuria and microscopic hematuria were observed among patients treated with CRESTOR. These findings were more frequent in patients taking CRESTOR 40 mg, though it was generally transient and was not associated with worsening renal function. Although the clinical significance of this finding is unknown, dose reduction should be considered for patients on CRESTOR therapy with unexplained persistent proteinuria and/or hematuria during routine urinalysis testing
• Increases in HbA1c and fasting serum glucose levels have been reported with HMG-CoA reductase inhibitors, including CRESTOR
• In the controlled clinical trials database, the most common adverse reactions were headache (3.7%), myalgia (3.1%), abdominal pain (2.6%), asthenia (2.5%), and nausea (2.2%)^#‡‡
• The dose range for CRESTOR is 5 mg to 40 mg orally once daily. The usual starting dose is 10 mg to 20 mg. Patients initiating CRESTOR therapy or switching from another statin should begin treatment with CRESTOR at the appropriate starting dose. After initiation or upon titration of CRESTOR, lipid levels should be analyzed within 2 to 4 weeks and the dosage adjusted accordingly. CRESTOR 40 mg should be used only for those patients not achieving their LDL-C goal with 20 mg

Indications

• CRESTOR is indicated as an adjunct to diet to reduce elevated Total-C, LDL-C, ApoB, non-HDL-C, and triglycerides, and to increase HDL-C in adult patients with primary hyperlipidemia or mixed dyslipidemia and to slow the progression of atherosclerosis in adult patients as part of a treatment strategy to lower Total-C and LDL-C to target levels
• CRESTOR is indicated to reduce the risk of myocardial infarction, stroke, and arterial revascularization procedures in patients without clinically evident coronary heart disease but with an increased risk of cardiovascular disease (CVD) based on age (men ≥50 and women ≥60), high-sensitivity C-reactive protein (hsCRP) ≥2 mg/L, and the presence of at least one additional CVD risk factor, such as hypertension, low HDL-C, smoking, or a family history of premature coronary heart disease

Read full Prescribing Information (PDF - 152k)

Please see the full Prescribing Information available at CrestorTouchPoints.com
CRESTOR is licensed from SHIONOGI & CO, LTD, Osaka, Japan.

CRESTOR is a registered trademark of the AstraZeneca group of companies.

©2011 AstraZeneca. All rights reserved. 1482202 12/11

• Privacy Statement | 
• Legal Information | 
• Contact Us | 
• Site Map

  This product information is intended for US health care professionals only.